Literature DB >> 22616911

Cancer therapy monitoring in xenografts by quantitative analysis of circulating tumor DNA.

Tobias M Gorges1, Johanna Schiller, Arndt Schmitz, Daniel Schuetzmann, Christoph Schatz, Thomas M Zollner, Thomas Krahn, Oliver von Ahsen.   

Abstract

CONTEXT: Circulating tumor DNA (ctDNA) is a promising biomarker in cancer.
MATERIALS AND METHODS: We generated xenograft models of cancer and detected ctDNA in plasma by qRCR targeting human AluJ sequences.
RESULTS: Our assay reached single cell sensitivity in vitro and a correlation between ctDNA amount and tumor size was observed in vivo. Treatment with a mitogen activated protein kinase kinase (MEK)-inhibitor (BAY 869766) reduced ctDNA levels. Using this assay, we also confirmed that high levels of cell-free DNA are found in cancer patients compared to healthy individuals. DISCUSSION AND
CONCLUSION: We show that ctDNA may be useful biomarker for monitoring tumor growth and treatment response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22616911     DOI: 10.3109/1354750X.2012.689133

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  15 in total

Review 1.  Circulating cell-free DNA for non-invasive cancer management.

Authors:  Caitlin M Stewart; Dana W Y Tsui
Journal:  Cancer Genet       Date:  2018-03-11

Review 2.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

3.  Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.

Authors:  Hongjuan Zhao; Rosalie Nolley; Andy M W Chan; Erinn B Rankin; Donna M Peehl
Journal:  Cancer Biol Ther       Date:  2016-08-11       Impact factor: 4.742

4.  Preconditioning with intravenous colitic cell-free DNA prevents DSS-colitis by altering TLR9-associated gene expression profile.

Authors:  Györgyi Műzes; Ferenc Sipos; István Fűri; Miklós Constantinovits; Sándor Spisák; Barnabás Wichmann; Gábor Valcz; Zsolt Tulassay; Béla Molnár
Journal:  Dig Dis Sci       Date:  2014-09-13       Impact factor: 3.199

5.  Intravenous administration of a single-dose free-circulating DNA of colitic origin improves severe murine DSS-colitis.

Authors:  Ferenc Sipos; Györgyi Műzes; István Fűri; Sándor Spisák; Barnabás Wichmann; Tiana M Germann; Miklós Constantinovits; Tibor Krenács; Zsolt Tulassay; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2014-04-11       Impact factor: 3.201

6.  Multi-marker analysis of circulating cell-free DNA toward personalized medicine for colorectal cancer.

Authors:  Florent Mouliere; Safia El Messaoudi; Dalong Pang; Anatoly Dritschilo; Alain R Thierry
Journal:  Mol Oncol       Date:  2014-03-24       Impact factor: 6.603

7.  High Interspecimen Variability in Nucleic Acid Extraction Efficiency Necessitates the Use of Spike-In Control for Accurate qPCR-based Measurement of Plasma Cell-Free DNA Levels.

Authors:  Grant C O'Connell; Paul D Chantler; Taura L Barr
Journal:  Lab Med       Date:  2017-11-08

8.  Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats.

Authors:  Dolores C García-Olmo; María G Picazo; Inmaculada Toboso; Ana I Asensio; Damián García-Olmo
Journal:  Mol Cancer       Date:  2013-02-04       Impact factor: 27.401

9.  An exposure to the oxidized DNA enhances both instability of genome and survival in cancer cells.

Authors:  Svetlana V Kostyuk; Marina S Konkova; Elizaveta S Ershova; Anna J Alekseeva; Tatiana D Smirnova; Sergey V Stukalov; Ekaterina A Kozhina; Nadezda V Shilova; Tatiana V Zolotukhina; Zhanna G Markova; Vera L Izhevskaya; Ancha Baranova; Natalia N Veiko
Journal:  PLoS One       Date:  2013-10-17       Impact factor: 3.240

10.  HER2-signaling pathway, JNK and ERKs kinases, and cancer stem-like cells are targets of Bozepinib small compound.

Authors:  Alberto Ramírez; Houria Boulaiz; Cynthia Morata-Tarifa; Macarena Perán; Gema Jiménez; Manuel Picon-Ruiz; Ahmad Agil; Olga Cruz-López; Ana Conejo-García; Joaquín M Campos; Ana Sánchez; María A García; Juan A Marchal
Journal:  Oncotarget       Date:  2014-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.